
<http://bio2rdf.org/drugbank:DB00072> a <http://schema.org/Drug> ;
	<http://schema.org/name> "Trastuzumab" ;
	<http://schema.org/description> "A recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with high affinity in a cell-based assay (Kd = 5 nM) to the extracellular domain of the human epidermal growth factor receptor protein. Produced in CHO cell culture.*" ;
	<http://schema.org/url> "https://www.drugbank.ca/drugs/DB00072" ;
	<http://schema.org/doseSchedule> "440 mg Powder for solution form with intravenous route" ;
	<http://schema.org/legalStatus> "investigational" ;
	<http://schema.org/mechanismOfAction> "Trastuzumab binds to the HER2 (or c-erbB2) proto-oncogene, an EGF receptor-like protein found on 20-30% of breast cancer cells. The binding leads to antibody mediated (complement mediated) killing of the HER2 positive cells." ;
	<http://schema.org/alternateName> "Anti HER2" ;
	<http://schema.org/sameAs> "https://www.drugbank.ca/drugs/DB00072" .
